IMV to Participate in Adelaide Capital’s Virtual COVID & Healthcare Mini Conference
22 April 2020 - 7:05AM
Business Wire
IMV Inc. (Nasdaq: IMV; TSX: IMV) a clinical-stage
biopharmaceutical company, today announced that Company’s
management will be participating in Adelaide Capital’s Virtual
COVID & Healthcare Mini Conference on April 23, 2020 from
12pm-5pm ET.
The conference will showcase the role Canadian companies are
playing to help fight the coronavirus pandemic. IMV will present
its plans around its DPX-COVID-19 candidate currently in
development with well-respected Canadian experts.
The conference will consist of 20-minute presentations followed
by a panel discussing some of the key issues involved in the crisis
today and a featured keynote by Next Edge Capital’s Eden Rahim
entitled “Signal from the Noise: A compass to finding COVID19
investment opportunities.” In participating in this conference, IMV
will be supporting the HandSan Project.
Please RSVP for this event directly through the link provided by
Adelaide Capital. IMV is scheduled to make its virtual presentation
at 2:20 pm. Eastern Time and will then take part in the panel
discussion scheduled later that day at 3:40 pm.
A copy of IMV’s presentation will be available in the “Events,
Webcasts and Presentations” of the investors section of the IMV
website. IMV will also continue to provide updates on the
development of DPX-COVID-19, and is working on a dedicated
DPX-COVID-19 page on its website.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform (DPX). This
patented technology leverages a novel mechanism of action that
enables the programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac in advanced ovarian cancer,
as well as in a combination therapy in multiple clinical studies
with Merck’s Keytruda®. IMV is also developing a DPX-based vaccine
to fight against COVID-19. Connect at www.imv-inc.com.
About Adelaide Capital
Adelaide Capital is a full-service Investor Relations firm that
brings to the table a unique and powerful perspective and a
re-engineered IR business model. Our extensive capital markets
experience allows us to go deeper, strategically assessing each
client company and tailoring a plan that charts the best path to
success. Specializing in small and mid-cap companies, our offering
is enhanced by a truly formidable factor—our personal connection to
a sizable and valuable network of investors throughout North
America and around the world.
Cautionary Language Regarding Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the Company’s progress in developing a DPX-based vaccine candidate
against COVID-19, the Company’s belief that the DPX-based platform
creates the opportunity for production of a COVID-19 vaccine, the
Company’s belief in the potential efficacy of its DPX-based vaccine
against COVID-19, the anticipated timing of the Company’s
preclinical assays, studies and clinical trials related to its
DPX-based vaccine against COVID-19 and the expected impact of
COVID-19 on the Company’s other clinical studies and trials and its
operations generally. Such statements should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks and uncertainties affecting the Company and
its products.
The Company assumes no responsibility to update forward-looking
statements in this press release except as required by law. These
forward-looking statements involve known and unknown risks and
uncertainties and those risks and uncertainties include, but are
not limited to, the Company’s ability to develop a DPX-based
vaccine candidate against the COVID-19 through the successful and
timely completion of preclinical assays, studies and clinical
trials, the receipt of all regulatory approvals by the Company to
commence and then continue clinical studies and trials, and, if
successful, the commercialization of its proposed vaccine candidate
related to COVID-19, the Company’s ability to raise sufficient
capital, including potentially through grant awards available in
Canada, to fund such clinical studies and trials and the production
of any COVID-19 vaccine, the ultimate applicability of any
third-party research and studies in related coronavirus and SARS
studies and sequencing, the Company’s ability to enter into
agreements with the proposed lead investigators to assist in the
clinical development on its vaccine candidate related to COVID-19,
the Company’s ability to collaborate with governmental authorities
with respect to such clinical development, the coverage and
applicability of the Company’s intellectual property rights to any
vaccine candidate related to COVID-19, the ability of the Company
to manufacture any vaccine candidate related to COVID-19 rapidly
and at scale, the ability for the Company to accurately assess and
anticipate the impact of COVID-19 on the Company’s other clinical
studies and trials and operations generally and other risks
detailed from time to time in the Company’s ongoing filings and in
its annual information form filed with the Canadian regulatory
authorities on SEDAR as www.sedar.com and with the United States
Securities and Exchange Commission on EDGAR at www.sec/edgar.
Investors are cautioned not to rely on these forward-looking
statements and are encouraged to read the Company’s continuous
disclosure documents which are available on SEDAR and on EDGAR.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200421005781/en/
Investor Relations Marc Jasmin, Senior Director,
Investor Relations, IMV O: (902) 492-1819, ext: 1042 M: (514)
617-9481 E: mjasmin@imv-inc.com Josh Rappaport, Director, Stern
IR O: (212) 362-1200 E: josh.rappaport@sternir.com Media
Delphine Davan, Director of Communications, IMV M: (514)
968-1046 E: ddavan@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024